Healthcare
The $1,000-per-month men’s longevity startup has been overhauled as the company learns from its mistakes.
Fresh from receiving FDA approval, the $1.3 billion medical device company is one of the stronger performers on the ASX this year. But short sellers sniff weakness.
The sale of 23andMe's genetic database to Regeneron shows gaps in Australia's cross-border data protection laws for sensitive health information.
